Acute infection requiring systemic antibiotics, antivirals, or antifungals within two weeks prior to first dose
Acute active infection requiring treatment (systemic antibiotics, antivirals, or antifungals) within 14 days prior cycle 1, day 1
Has an uncontrolled infection requiring intravenous antibiotics, antivirals, or antifungals, known human immunodeficiency virus infection, or active hepatitis B or C infection.
Acute active infection requiring systemic antibiotics, antivirals, or antifungals within two weeks prior to first dose
Acute active infection requiring systemic antibiotics, antivirals, or antifungals within 14 days prior to first dose
Serious infection requiring oral or IV antibiotics/antifungals/antivirals and/or hospitalization within 28 days prior to screening\r\n* Patients on prophylactic oral antibiotics, antifungals and antivirals due to prolonged neutropenia in the absence of documented infection are eligible\r\n* Patients who are treated with IV antibiotics for neutropenic fever, are eligible if no infectious etiology was determined and the last dose of antibiotics was >= 7 days from cycle 1, day 1
Has an uncontrolled infection requiring IV antibiotics, antivirals, or antifungals
Uncontrolled infection requiring systemic antibiotics/antivirals/antifungals
Uncontrolled (i.e., clinically unstable) infection requiring parenteral antibiotics, antivirals, or antifungals within one week prior to first dose; however, prophylactic use of these agents is acceptable even if parenteral
Acute infection requiring systemic antibiotics, antivirals, or antifungals within two weeks prior to first dose
Patients with active infections requiring intravenous (IV) antibiotic/antiviral therapy are not eligible for entry onto the study until resolution of the infection; patients on prophylactic antibiotics, antifungals or antivirals are acceptable
Active infection requiring antibiotics or antifungals within 7 days prior to first dose of study drug
Treatment with intravenous (systemic antibiotics, antivirals, or antifungals) within 14 days prior to start of treatment
Chronic or current active infectious disease requiring systemic antibiotics, antifungals, or antivirals
Subjects with an uncontrolled infection requiring intravenous antibiotics, antivirals, or antifungals, known human immunodeficiency virus infection, or active hepatitis A, B or C infection
Infection requiring parenteral antibiotics, antivirals, or antifungals within 2 weeks prior to C1D1.
Acute infection requiring treatment (IV antibiotics, antivirals, or antifungals) within 14 days prior to initiation of study
Acute infection requiring systemic anti-infectives, antivirals, or antifungals within two weeks prior to first dose
Patients with an active infection requiring intravenous antivirals, antibiotics or antifungals; patients on prolonged antifungal therapy are still eligible if they are culture negative and biopsy negative in suspected residual radiographic lesions have stabilized or regressed and they meet other organ function criteria
Has an uncontrolled infection requiring intravenous antibiotics, antivirals, or antifungals, known human immunodeficiency virus infection, or active hepatitis B or C infection.
Uncontrolled infection requiring parenteral antibiotics, antivirals, or antifungals within one week prior to first dose; patients with controlled infection or on prophylactic antibiotics are permitted in the study
Uncontrolled active infection requiring systemic antibiotics, antivirals, or antifungals within one week prior to first dose; prophylactic antimicrobials are permitted
Must not have acute active infection requiring treatment (systemic antibiotics, antivirals, or antifungals) within 14 days prior to enrollment.
Acute infection requiring systemic antibiotics, antivirals, or antifungals within 14 days prior to first dose
Uncontrolled infection requiring parenteral antibiotics, antivirals, or antifungals within 14 days prior to first dose; patients with controlled infection or on prophylactic antibiotics are permitted in the study
Patients who have an acute active infection requiring treatment (systemic antibiotics, antivirals, or antifungals) within 14 days prior to registration are NOT eligible for participation
Has an uncontrolled infection requiring intravenous antibiotics, antivirals, or antifungals.
Uncontrolled infection requiring parenteral antibiotics, antivirals, or antifungals within one week prior to first dose; patients with controlled infection or on prophylactic antibiotics are permitted in the study
Active infection requiring antibiotics or antifungals within 7 days prior to first dose of study drug
Active infection requiring parenteral antibiotics, antivirals, or antifungals within 2 weeks prior to first dose of study drug
Have active serious infection uncontrolled by antibiotics or antifungals
Ongoing or active infection; treatment with systemic antibiotics or antifungals for ongoing or recurrent infection (topical use of antibiotics or antifungals is allowed)
Clinically relevant active infection requiring treatment (antibiotics, antivirals, antifungals)
Acute infection requiring treatment (systemic antibiotics, antivirals, or antifungals) within 14 days prior to initiation of study
Active infection requiring antibiotics or antifungals within 7 days prior to first dose of study drug
Uncontrolled active infection requiring parenteral antibiotics, antivirals or antifungals within 1 week prior to the first date of study treatment
Acute infection requiring treatment (systemic antibiotics, antivirals, or antifungals) within 14 days prior to initiation of study
Uncontrolled infection requiring parenteral antibiotics, antivirals, or antifungals within one week prior to first dose; patients with controlled infection or on prophylactic antibiotics are permitted in the study
Uncontrolled active infection requiring parenteral antibiotics, antivirals, or antifungals within one week prior to first dose
Acute active infection requiring treatment (IV antibiotics, antivirals, or antifungals) within 14 days prior to the first day of treatment
Uncontrolled active infection requiring parenteral antibiotics, antivirals, or antifungals within one week prior to first dose
Presence of an acute infection requiring active treatment with antibiotics/antivirals; prophylactic administration is allowed
No acute active infection requiring treatment (systemic antibiotics, antivirals, or antifungals) within 14 days prior to cycle 1 day 1
Acute active infection requiring treatment (systemic antibiotics, antivirals, or antifungals) within 14 days prior to signing consent
Active infection requiring systemic antibiotics, antivirals, or antifungals within 2 weeks prior to first dose
Acute active infection requiring systemic antibiotics, antivirals, or antifungals within two weeks prior to first dose
Active infection (including HIV/acquired immune deficiency syndrome [AIDS], hepatitis B, or hepatitis C infection) requiring systemic antibiotics, antivirals, or antifungals
Oral or IV antibiotics, antifungals, or antivirals within 1 week, with the exception of prophylactic oral agents. Note: In the event that a subject requires the chronic use of antivirals, Medical Monitor permission is required for entry into the study.
Uncontrolled active infection requiring parenteral antibiotics, antivirals, or antifungals within one week prior to first dose
Uncontrolled infection requiring parenteral antibiotics, antivirals, or antifungals within one week prior to first dose; patients with controlled infection or on prophylactic antibiotics are permitted in the study
Uncontrolled infection requiring IV antibiotics, antivirals, or antifungals, known human immunodeficiency virus (HIV) infection, or active hepatitis B or C infection.
Acute active infection requiring treatment (systemic antibiotics, antivirals, or antifungals) within 14 days prior to enrollment
Uncontrolled infection requiring parenteral antibiotics, antivirals, or antifungals within one week prior to first dose; patients with controlled infection or on prophylactic antibiotics are permitted in the study
Has an uncontrolled infection requiring IV antibiotics, antivirals, or antifungals, known human immunodeficiency virus infection, or active hepatitis B or C infection.
Acute active infection requiring systemic antibiotics, antivirals, or antifungals within 14 days prior to first dose
Acute active infection requiring treatment (systemic antibiotics, antivirals, or antifungals) within 14 days prior to randomization
Acute active infection requiring systemic antibiotics, antivirals, or antifungals within 14 days prior to first dose
Acute active infection requiring treatment (systemic antibiotics, antivirals, or antifungals) within 14 days prior to randomization
Uncontrolled infection requiring parenteral antibiotics, antivirals, or antifungals within one week prior to first dose; patients with controlled infection or on prophylactic antibiotics are permitted in the study
Have an active, clinically significant serious infection requiring intravenous treatment with antibiotics, antivirals, or antifungals.
Uncontrolled active infection requiring parenteral antibiotics, antivirals, or antifungals within one week prior to the first dose; active infection with concurrent treatment is acceptable only if the patient is clinically stable
Uncontrolled active infection requiring parenteral antibiotics, antivirals, or antifungals within 1 week prior to C1D1.
Has an uncontrolled infection requiring intravenous antibiotics, antivirals, or antifungals, known human immunodeficiency virus infection, or tested positive for active hepatitis B or C infection
